Alnylam price target lowered to $225 from $250 at Chardan

Chardan lowered the firm’s price target on Alnylam Pharmaceuticals to $225 from $250 and keeps a Buy rating on the shares. The company announced an updated statistical analysis plan for the Phase III HELIOS-B study which only served to increase investor concern about a negative data readout, the analyst tells investors in a research note. The firm says that while the “11th hour change in the statistical analysis plan is disconcerting,” it would “rather management implement this change while they still can, which, perhaps can still result in a study outcome that can support an approval of Amvuttra for ATTR-CM, rather than just proceed” under the prior plan and just miss a statically significance outcome.